OBJECTIVE: This article aims to identify the opportunities and risks of Artificial Intelligence tools (AIT) applied to clinical practice, while also reflecting on their impact on the doctor-patient relationship.
BACKGROUND: In the evolving field of forensic medicine, artificial intelligence (AI) technologies may revolutionize traditional autopsy practices by enhancing the precision and efficiency of postmortem examinations.
BACKGROUND: The analysis, interpretation and storage of information is entrusted to the individual expert, who bases his judgments on the knowledge resulting from the experience. The aim of this experimental study is to analyse and introduce a new li...
OBJECTIVE: Artificial intelligence (AI) is the ability of a computer machine to display human capabilities such as reasoning, learning, planning, and creativity. Such processing technology receives the data (already prepared or collected), processes ...
BACKGROUND: The human microbiome, consisting of diverse bacte-rial, fungal, protozoan and viral species, exerts a profound influence on various physiological processes and disease susceptibility. However, the complexity of microbiome data has present...
BACKGROUND: Social robotics is a research field aimed at providing robots with skills related to social behavior and natural human interaction. Many studies have demonstrated the efficacy of these robots as socio-communicative mediators. Others have ...
The entrance of Artificial Intelligence (AI) as a new actor in the doctor-patient relationship has encouraged important legal and ethi-cal considerations among the experts. On the one hand, there is the request to establish a new and dedicated legal ...
Healthcare expenses will be the most relevant policy issue for most governments in the EU and in the USA. This expenditure can be associated with two major key categories: demographic and economic drivers. Factors driving healthcare expenditure were ...
OBJECTIVES: The aim of the current study was to analyze the susceptibility of gram-positive and -negative clinical isolates to a novel des-F(6)-quinolone (nemonoxacin) and other selected antimicrobial agents.